DiscoverThe Lancet Rheumatology in conversation withFabian Müller and Melanie Hagen on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy
Fabian Müller and Melanie Hagen on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy

Fabian Müller and Melanie Hagen on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy

Update: 2025-06-03
Share

Description

This is the third and final episode of our mini-series on cell-based therapies in rheumatology, with Professor Fabian Müller and Dr Melanie Hagen from the Erlangen University, Germany. We discuss their recently published a study on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy in patients with autoimmune disease, as well as the recent successes of CAR T-cell therapy, ideal patient selection, and future directions.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00091-8/fulltext?dgcid=buzzsprout_icw_podcast_Jun_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Fabian Müller and Melanie Hagen on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy

Fabian Müller and Melanie Hagen on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy

The Lancet Group